» Articles » PMID: 15192701

PS1 Activates PI3K Thus Inhibiting GSK-3 Activity and Tau Overphosphorylation: Effects of FAD Mutations

Overview
Journal EMBO J
Date 2004 Jun 12
PMID 15192701
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

Phosphatidylinositol 3-kinase (PI3K) promotes cell survival and communication by activating its downstream effector Akt kinase. Here we show that PS1, a protein involved in familial Alzheimer's disease (FAD), promotes cell survival by activating the PI3K/Akt cell survival signaling. This function of PS1 is unaffected by gamma-secretase inhibitors. Pharmacological and genetic evidence indicates that PS1 acts upstream of Akt, at or before PI3K kinase. PS1 forms complexes with the p85 subunit of PI3K and promotes cadherin/PI3K association. Furthermore, conditions that inhibit this association prevent the PS1-induced PI3K/Akt activation, indicating that PS1 stimulates PI3K/Akt signaling by promoting cadherin/PI3K association. By activating PI3K/Akt signaling, PS1 promotes phosphorylation/inactivation of glycogen synthase kinase-3 (GSK-3), suppresses GSK-3-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. PS1 FAD mutations inhibit the PS1-dependent PI3K/Akt activation, thus promoting GSK-3 activity and tau overphosphorylation at AD-related residues. Our data raise the possibility that PS1 may prevent development of AD pathology by activating the PI3K/Akt signaling pathway. In contrast, FAD mutations may promote AD pathology by inhibiting this pathway.

Citing Articles

Molecular Mechanisms of Alzheimer's Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy.

Ahn E, Park J Cells. 2025; 14(2).

PMID: 39851517 PMC: 11764136. DOI: 10.3390/cells14020089.


BMAL1 ameliorates type 2 diabetes-induced cognitive impairment via AREG upregulation and PI3K/Akt/GSK-3β pathway activation.

Xu J, Li C, Fan R, Yin J, Xie L, Peng X Cell Commun Signal. 2025; 23(1):7.

PMID: 39762888 PMC: 11705844. DOI: 10.1186/s12964-024-02019-5.


Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer's disease.

Karati D, Meur S, Roy S, Mukherjee S, Debnath B, Jha S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39432068 DOI: 10.1007/s00210-024-03500-1.


The role of PI3K signaling pathway in Alzheimer's disease.

Pan J, Yao Q, Wang Y, Chang S, Li C, Wu Y Front Aging Neurosci. 2024; 16:1459025.

PMID: 39399315 PMC: 11466886. DOI: 10.3389/fnagi.2024.1459025.


Updates in Alzheimer's disease: from basic research to diagnosis and therapies.

Liu E, Zhang Y, Wang J Transl Neurodegener. 2024; 13(1):45.

PMID: 39232848 PMC: 11373277. DOI: 10.1186/s40035-024-00432-x.


References
1.
Sperber B, Leight S, Goedert M, Lee V . Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett. 1995; 197(2):149-53. DOI: 10.1016/0304-3940(95)11902-9. View

2.
Bursztajn S, DeSouza R, McPhie D, Berman S, Shioi J, Robakis N . Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis. J Neurosci. 1998; 18(23):9790-9. PMC: 6793279. View

3.
Rodriguez-Viciana P, Warne P, Vanhaesebroeck B, Waterfield M, Downward J . Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 1996; 15(10):2442-51. PMC: 450176. View

4.
Thinakaran G, Borchelt D, Lee M, Slunt H, Spitzer L, Kim G . Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996; 17(1):181-90. DOI: 10.1016/s0896-6273(00)80291-3. View

5.
Datta S, Brunet A, Greenberg M . Cellular survival: a play in three Akts. Genes Dev. 1999; 13(22):2905-27. DOI: 10.1101/gad.13.22.2905. View